Financials' strength keeps ISEQ up
Warner Chilcott's FDA approval for menopause symptom drug Femtrace has not helped the company share price this morning, after it fell by nine cent to €8.87.
The company expects to launch Femtrace tablets in the first quarter of 2005.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





